MCID: LPD008
MIFTS: 58

Lipid Metabolism Disorder malady

Categories: Metabolic diseases

Aliases & Classifications for Lipid Metabolism Disorder

Aliases & Descriptions for Lipid Metabolism Disorder:

Name: Lipid Metabolism Disorder 12 29 14
Dyslipidemia 12 52 14
Fatty Acid Metabolism Disorder 12 29
Lipid Metabolism Disorders 41 69
Disorder of Fatty Acid Metabolism 69
Lipid Metabolism, Inborn Errors 42
Dyslipidemias 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3146
MeSH 42 D008052
ICD10 33 E71.3
UMLS 69 C0023772

Summaries for Lipid Metabolism Disorder

MedlinePlus : 41 metabolism is the process your body uses to make energy from the food you eat. food is made up of proteins, carbohydrates, and fats. chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. your body can use this fuel right away, or it can store the energy in your body tissues. if you have a metabolic disorder, something goes wrong with this process. lipid metabolism disorders, such as gaucher disease and tay-sachs disease, involve lipids. lipids are fats or fat-like substances. they include oils, fatty acids, waxes, and cholesterol. if you have one of these disorders, you may not have enough enzymes to break down lipids. or the enzymes may not work properly and your body can't convert the fats into energy. they cause a harmful amount of lipids to build up in your body. over time, that can damage your cells and tissues, especially in the brain, peripheral nervous system, liver, spleen, and bone marrow. many of these disorders can be very serious, or sometimes even fatal. these disorders are inherited. newborn babies get screened for some of them, using blood tests. if there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. enzyme replacement therapies can help with a few of these disorders. for others, there is no treatment. medicines, blood transfusions, and other procedures may help with complications.

MalaCards based summary : Lipid Metabolism Disorder, also known as dyslipidemia, is related to failure to thrive and dyslipidemia caused by citrin deficiency and hypoalphalipoproteinemia. An important gene associated with Lipid Metabolism Disorder is RBP4 (Retinol Binding Protein 4), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Aripiprazole and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include testes, bone and liver, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Disease Ontology : 12 An inherited metabolic disorder that involves the creation and degradation of lipids.

Related Diseases for Lipid Metabolism Disorder

Diseases related to Lipid Metabolism Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
id Related Disease Score Top Affiliating Genes
1 failure to thrive and dyslipidemia caused by citrin deficiency 11.9
2 hypoalphalipoproteinemia 11.1
3 fatty liver disease, nonalcoholic 1 10.9
4 hyperlipidemia type 3 10.8
5 gallbladder disease 1 10.7
6 citrullinemia, type ii, neonatal-onset 10.7
7 prediabetes syndrome 10.7
8 hypolipoproteinemia 10.7
9 lipodystrophy, familial partial, 2 10.7
10 lipodystrophy, familial partial, type 6 10.7
11 lipodystrophy, familial partial, type 3 10.7
12 chylomicron retention disease 10.7
13 carnitine palmitoyltransferase ii deficiency 10.7
14 acyl-coa dehydrogenase, short-chain, deficiency of 10.7
15 tay-sachs disease 10.7
16 acyl-coa dehydrogenase, medium chain, deficiency of 10.7
17 steroid inherited metabolic disorder 10.7
18 sitosterolemia 10.7
19 gaucher's disease 10.7
20 barth syndrome 10.7
21 vlcad deficiency 10.7
22 alport syndrome and thin basement membrane nephropathy 10.3 APOE LPL
23 acquired angioedema 10.3 ADIPOQ PPARG
24 acute infection of pinna 10.3 CRP INS
25 zap-70 deficiency 10.3 APOB APOE
26 transient retinal arterial occlusion 10.3 APOA1 APOB HMGCR
27 stickler sydrome, type i, nonsyndromic ocular 10.3 APOA1 APOB LEP
28 keratoconus 4 10.3 APOB APOE
29 dentinogenesis imperfecta type 2 10.3 APOB APOE HMGCR
30 leg dermatosis 10.2 ADIPOQ INS LEP
31 hyperphosphatemia 10.2 INS LEP PPARG
32 acrocephalopolydactyly 10.2 ADIPOQ LEP
33 neurogenic arthropathy 10.2 ADIPOQ INS LEP
34 fetal warfarin syndrome 10.2 APOA1 APOB INS LEP
35 exostosis 10.2 APOB HNF4A INS LEP
36 iida kannari syndrome 10.2 ADIPOQ INS PPARA PPARG
37 primary pigmented nodular adrenocortical disease 10.2 APOA1 APOB APOE INS
38 polycystic kidney disease, infantile severe, with tuberous sclerosis 10.2 LIPC LPL
39 mitochondrial complex iii deficiency, nuclear type 4 10.2 APOA1 APOB MTTP
40 antidepressant type abuse 10.2 ADIPOQ INS LEP RBP4
41 alzheimer disease 19, late onset 10.2 APOB APOE LPA
42 autosomal recessive congenital ichthyosis 10.2 INS LEP PPARA PPARG
43 meningitis 10.2 ADIPOQ INS LEP PPARA
44 abducens nerve neoplasm 10.2 APOA5 LIPC LPL
45 fibrosarcoma of bone 10.2 APOB HMGCR LPA
46 thymus clear cell carcinoma 10.2 ADIPOQ INS LEP PPARG
47 anaplastic ganglioglioma 10.2 APOA1 CRP LPA
48 hypercholesterolemia, due to ligand-defective apo b 10.2 APOB APOE MTTP
49 asphyxia neonatorum 10.2 APOE LPA LPL
50 gallbladder disease 4 10.2 APOB HMGCR MTTP

Comorbidity relations with Lipid Metabolism Disorder via Phenotypic Disease Network (PDN):


Chronic Myocardial Ischemia Hypertension, Essential
Intermediate Coronary Syndrome Ischemic Heart Disease

Graphical network of the top 20 diseases related to Lipid Metabolism Disorder:



Diseases related to Lipid Metabolism Disorder

Symptoms & Phenotypes for Lipid Metabolism Disorder

GenomeRNAi Phenotypes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.7 APOA1 APOA5 APOB APOC3 APOE CETP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE LPL

MGI Mouse Phenotypes related to Lipid Metabolism Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 HNF4A INS LEP LIPC LPL MTTP
2 cardiovascular system MP:0005385 10.18 ADIPOQ APOA1 APOB APOE CRP INS
3 cellular MP:0005384 10.11 LPL PPARA PPARG RBP4 ADIPOQ APOA1
4 growth/size/body region MP:0005378 10.1 ADIPOQ APOB APOE COG2 HMGCR HNF4A
5 adipose tissue MP:0005375 9.98 ADIPOQ APOE INS LEP LPL PPARA
6 integument MP:0010771 9.76 ADIPOQ APOA1 APOE INS LEP LPL
7 liver/biliary system MP:0005370 9.73 ADIPOQ APOA1 APOB APOE HMGCR HNF4A
8 muscle MP:0005369 9.28 PPARG RBP4 ADIPOQ APOB APOE INS

Drugs & Therapeutics for Lipid Metabolism Disorder

Drugs for Lipid Metabolism Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1025)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 1 129722-12-9 60795
2
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
3
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Phase 1 49562-28-9 3339
4
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1 163222-33-1 150311
5
Bisoprolol Approved Phase 4 66722-44-9 2405
6
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
7
Diltiazem Approved Phase 4,Phase 3,Phase 1,Phase 2 42399-41-7 39186
8
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1 88150-42-9 2162
9
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2 58-93-5 3639
10
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
11
Nifedipine Approved Phase 4 21829-25-4 4485
12
Pravastatin Approved Phase 4,Phase 2,Phase 3,Phase 1 81093-37-0 54687
13
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 83-43-2 6741
15
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
16
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 128794-94-5 5281078
17
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 24280-93-1 446541
18
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
19
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
20
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
21
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 104987-11-3 445643 439492
22
Cilostazol Approved Phase 4,Phase 1 73963-72-1 2754
23
Probucol Approved Phase 4,Phase 3 23288-49-5 4912
24
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
25
Fluvastatin Approved Phase 4,Phase 3 93957-54-1 1548972
26
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
27
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
28
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2 152923-56-3, 179045-86-4
29
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-78-2 2244
30
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2 136470-78-5 65140 441300
31
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
32
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 155213-67-5 392622
33
Lopinavir Approved Phase 4,Phase 2,Phase 1 192725-17-0 92727
34
Nevirapine Approved Phase 4,Phase 3,Phase 2 129618-40-2 4463
35
Zidovudine Approved Phase 4,Phase 2,Phase 1 30516-87-1 35370
36
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
37
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
38
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
39
Linagliptin Approved Phase 4,Phase 3 668270-12-0 10096344
40
Adalimumab Approved Phase 4 331731-18-1 16219006
41
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 637568 5271565
42
Zinc Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7440-66-6 32051 23994
43
Sertraline Approved Phase 4 79617-96-2 68617
44
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
45
Alogliptin Approved Phase 4,Phase 3,Phase 2 850649-61-5 11450633
46
Glimepiride Approved Phase 4,Phase 3,Phase 2 93479-97-1 3476
47
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757 53477783
48
Norethindrone Approved Phase 4 68-22-4 6230
49
Alendronate Approved Phase 4,Phase 2,Phase 3 121268-17-5, 66376-36-1 2088
50
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959

Interventional clinical trials:

(show top 50) (show all 5142)
id Name Status NCT ID Phase
1 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4
2 An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin Unknown status NCT00678743 Phase 4
3 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4
4 Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin Unknown status NCT01613729 Phase 4
5 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT) Unknown status NCT00712049 Phase 4
6 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4
7 The HDL Particle Protection Study Unknown status NCT02125682 Phase 4
8 The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control Unknown status NCT00282659 Phase 4
9 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4
10 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4
11 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4
12 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4
13 A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4
14 Rajavithi Health Promotion Project (Population Base Cohort) Unknown status NCT00368095 Phase 4
15 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4
16 The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4
17 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4
18 To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Unknown status NCT02098460 Phase 4
19 Probiotic BIO-25 as a Supplement to Statins for the Treatment of Hypercholesterolemia Unknown status NCT01849185 Phase 4
20 The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels Unknown status NCT01712867 Phase 4
21 Lovaza Mechanisms of Action Unknown status NCT01301794 Phase 4
22 Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia Unknown status NCT00972829 Phase 4
23 Triglyceride Lowering Study Unknown status NCT00934219 Phase 4
24 Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia Unknown status NCT00746811 Phase 4
25 Fluvastatin After Heart Transplantation Unknown status NCT00421005 Phase 4
26 Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy? Unknown status NCT00295373 Phase 4
27 Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure Unknown status NCT00716573 Phase 4
28 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Unknown status NCT02328963 Phase 4
29 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
30 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4
31 The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients Unknown status NCT00758927 Phase 4
32 Japanese Primary Prevention Project With Aspirin Unknown status NCT00225849 Phase 4
33 Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia Unknown status NCT01480687 Phase 4
34 Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes Unknown status NCT01322711 Phase 4
35 Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH) Unknown status NCT00885872 Phase 4
36 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4
37 A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4
38 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Unknown status NCT00843661 Phase 4
39 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4
40 Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease Unknown status NCT00487630 Phase 4
41 SHARE: Simple HAART With Abacavir, Reyataz, and Epivir Unknown status NCT00426296 Phase 4
42 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4
43 Multiple Grain in Type 2 Diabetes Unknown status NCT00337337 Phase 4
44 Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome Unknown status NCT01168700 Phase 4
45 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4
46 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
47 Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes Unknown status NCT01185236 Phase 4
48 Thyroid Study Type 2 Diabetes Mellitus (T2DM) Unknown status NCT01379170 Phase 4
49 Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin. Unknown status NCT00404599 Phase 4
50 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4

Search NIH Clinical Center for Lipid Metabolism Disorder

Cochrane evidence based reviews: lipid metabolism, inborn errors

Genetic Tests for Lipid Metabolism Disorder

Genetic tests related to Lipid Metabolism Disorder:

id Genetic test Affiliating Genes
1 Disorder of Fatty Acid Metabolism 29
2 Abnormality of Lipid Metabolism 29

Anatomical Context for Lipid Metabolism Disorder

MalaCards organs/tissues related to Lipid Metabolism Disorder:

39
Testes, Bone, Liver, Bone Marrow, Brain, Spleen, Heart

Publications for Lipid Metabolism Disorder

Articles related to Lipid Metabolism Disorder:

(show all 26)
id Title Authors Year
1
Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4I+ miR122 Pathway. ( 27011261 )
2016
2
HNF-4I+ regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in Type 2 diabetic mice and in palmitate-treated HepG2 cells. ( 27592052 )
2016
3
Angelica sinensis polysaccharide regulates glucose and lipid metabolism disorder in prediabetic and streptozotocin-induced diabetic mice through the elevation of glycogen levels and reduction of inflammatory factors. ( 25630053 )
2015
4
Yhhu981, a novel compound, stimulates fatty acid oxidation via the activation of AMPK and ameliorates lipid metabolism disorder in ob/ob mice. ( 25732571 )
2015
5
L-Carnitine intake prevents irregular feeding-induced obesity and lipid metabolism disorder. ( 25445284 )
2015
6
[Genetically determined lipid metabolism disorders due to oral intake of technogenic hyperchlorination products]. ( 26596112 )
2015
7
Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway. ( 25885422 )
2015
8
Oral Exposure of Mice to Carbendazim Induces Hepatic Lipid Metabolism Disorder and Gut Microbiota Dysbiosis. ( 26071454 )
2015
9
Green tea extract containing a highly absorbent catechin prevents diet-induced lipid metabolism disorder. ( 24067358 )
2013
10
Ameliorating effect of mother tincture of Syzygium jambolanum on carbohydrate and lipid metabolic disorders in streptozotocin-induced diabetic rat: Homeopathic remedy. ( 23633838 )
2013
11
Abnormal barrier function in the pathogenesis of ichthyosis: therapeutic implications for lipid metabolic disorders. ( 22507046 )
2012
12
Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy. ( 22213519 )
2012
13
Quercetin Protects against Cadmium-Induced Renal Uric Acid Transport System Alteration and Lipid Metabolism Disorder in Rats. ( 22690247 )
2012
14
Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. ( 21093950 )
2011
15
The model of rat lipid metabolism disorder induced by chronic stress accompanying high-fat-diet. ( 21871127 )
2011
16
Chanarin-Dorfman syndrome: clinical features of a rare lipid metabolism disorder. ( 19250403 )
2009
17
Fat and cholesterol diet induced lipid metabolic disorders and insulin resistance in rabbit. ( 19301228 )
2009
18
[Carbohydrate and lipid metabolism disorders in obese children and adolescents]. ( 15858253 )
2004
19
[Interconnection between insulin resistance and lipid metabolism disorders in obese patients]. ( 12469622 )
2002
20
[Pharmacologic treatment of lipid metabolism disorders]. ( 9214849 )
1996
21
[The evaluation of a method for determining apolipoproteins as a sensitive indicator in assessing lipid metabolic disorder in a population at risk for essential arterial hypertension (EAHT)]. ( 9455355 )
1995
22
[Lipid metabolic disorders and lipid peroxidation in patients with the nephrotic syndrome]. ( 8079411 )
1994
23
[Relationship between lipid metabolism disorders and age of first manifestations of coronary heart disease]. ( 1509793 )
1992
24
[Pathophysiology and therapy of lipid metabolism disorders in kidney diseases]. ( 1921228 )
1991
25
[Restriction polymorphism in patients with lipid metabolism disorders and ischemic heart disease]. ( 1979835 )
1990
26
A lipid metabolic disorder: disseminated lipogranulomatosis; a syndrome with similarity to, and important difference from, Niemann-Pick and Hand-SchA1ller-Christian disease. ( 12975849 )
1952

Variations for Lipid Metabolism Disorder

Expression for Lipid Metabolism Disorder

Search GEO for disease gene expression data for Lipid Metabolism Disorder.

Pathways for Lipid Metabolism Disorder

Pathways related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 23)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
2
Show member pathways
12.81 ADIPOQ APOA1 APOA5 HMGCR LEP LPL
3
Show member pathways
12.61 APOA1 APOB APOC3 APOE LPL RBP4
4 12.43 ADIPOQ APOE HNF4A INS PPARG
5
Show member pathways
12.39 ADIPOQ HMGCR HNF4A INS LEP PPARG
6
Show member pathways
12.28 APOA1 APOB APOC3 APOE LPL RBP4
7
Show member pathways
12.27 APOA1 APOB APOE CRP INS
9
Show member pathways
12.19 APOA1 APOA5 APOB APOC3 APOE CETP
10 11.85 ADIPOQ INS LEP LPL PPARA PPARG
11 11.84 ADIPOQ INS LEP LPL PPARG
12
Show member pathways
11.8 APOA1 APOB APOE
13
Show member pathways
11.76 ADIPOQ HNF4A INS
14
Show member pathways
11.73 HNF4A PPARA PPARG
15 11.63 HMGCR INS LPL PPARG RBP4
16 11.61 ADIPOQ LEP PPARA
17 11.56 ADIPOQ APOA1 APOA5 APOC3 LPL PPARA
18
Show member pathways
11.4 APOA1 APOB MTTP
19 11.4 APOA1 HNF4A INS
20
Show member pathways
11.15 APOA1 APOA5 APOB APOC3 APOE CETP
21 11.13 ADIPOQ LEP PPARG
22 11.12 APOA1 APOA5 APOC3 PPARA
23 11.07 ADIPOQ LEP PPARG

GO Terms for Lipid Metabolism Disorder

Cellular components related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.98 APOA1 APOA5 APOB APOE INS LIPC
2 early endosome GO:0005769 9.8 APOA1 APOB APOC3 APOE
3 high-density lipoprotein particle GO:0034364 9.72 APOA1 APOA5 APOE CETP LIPC
4 low-density lipoprotein particle GO:0034362 9.71 APOA1 APOA5 APOB APOE
5 endocytic vesicle lumen GO:0071682 9.63 APOA1 APOB APOE
6 endosome lumen GO:0031904 9.51 APOB INS
7 spherical high-density lipoprotein particle GO:0034366 9.48 APOA1 APOC3
8 intermediate-density lipoprotein particle GO:0034363 9.46 APOA1 APOB APOC3 APOE
9 very-low-density lipoprotein particle GO:0034361 9.43 APOA1 APOA5 APOB APOC3 APOE LPL
10 chylomicron GO:0042627 9.1 APOA1 APOA5 APOB APOC3 APOE LPL
11 extracellular region GO:0005576 10.21 ADIPOQ APOA1 APOA5 APOB